Latest United Kingdom News

Sea Forest has reported a sharp lift in SeaFeed revenue during its first full year as an ASX-listed company, but remains loss-making as it funds production and market expansion. The methane-reduction specialist ended FY26 with $27.8 million in cash and term deposits and no borrowings.

IODM Limited (ASX:IOD) increased FY2026 revenue by 16.9% and narrowed its net loss, but auditors flagged material uncertainty over the company’s ability to continue as a going concern. A post-year-end A$1.00 million placement is funding an expansion into North American universities while the business remains heavily reliant on external capital.

Enlitic has secured a US$806,000 contract to migrate 10.6 million medical imaging studies for University of Michigan Health-Sparrow. The project also gives its Ensight platform a first active integration with Sectra’s enterprise imaging environment.

Nufarm is pairing a narrower crop-protection portfolio with heavier investment in seeds and tighter capital controls as it targets A$370 million to A$380 million in FY26 underlying EBITDA. The company has reaffirmed positive free cash flow, leverage of about 2.0 times and a A$50 million cost-saving program due to reach run-rate by the end of FY27.

GWA Group delivered its third consecutive year of volume growth in FY26, lifting revenue, normalised EBIT and its fully franked dividend despite weak housing and renovation conditions. The trade-off was a sharp decline in operating cash flow and higher net debt following inventory purchases and a $25 million share buyback.

Rua Bioscience delivered a sharp rise in customer revenue and secured a UK agreement expected to generate NZ$10 million over two years. But PwC disclaimed an audit opinion, warning the company may not have enough cash without another capital raise.

Biome Australia Limited (ASX:BIO) delivered its second consecutive profitable year in FY26, with revenue rising 30% to $23.9 million and operating cash flow turning positive. But the headline $3.6 million profit includes a $2.4 million deferred tax benefit, leaving FY27 execution as the real test of the company’s growth plan.

Orthocell has recorded the first commercial sales of its Remplir nerve repair product in Thailand, opening a new market estimated at US$84 million. The launch gives the company another distributor-led growth channel, although near-term sales are expected to remain modest.

Wesfarmers Limited has updated its final dividend details for FY2026, declaring a fully franked ordinary dividend of AUD 1.20 per share payable on 7 October 2026. Shareholders can elect to receive payments in Australian, New Zealand, or British currencies, with a fully available Dividend Reinvestment Plan restricted to Australian and New Zealand addresses.

Commonwealth Bank of Australia updates its final dividend details for FY26, offering a fully franked AUD 2.70 per share payout with flexible currency payments and a full Dividend Reinvestment Plan.

Lendlease Group has updated its FY26 half-year dividend details, confirming the DRP price after the VWAP period and outlining dividend equivalents in AUD, NZD, and GBP. The unfranked dividend of AUD 0.0955 per security will be paid on 16 September 2026.

Microba Life Sciences delivered a mixed FY26, with overall revenue slipping 5.8% to $14.76 million and a statutory loss widening 38.7% to $20.7 million. The company’s strategic pivot to core microbiome testing paid off with a 92% surge in core testing revenue and record test volumes in Australia and the UK. Despite the headline loss, underlying loss improved 11% thanks to cost cuts and AI-driven efficiencies. Microba is gearing up for the October launch of its GI Navigator diagnostic and targeting cash flow break-even on a run-rate basis in calendar 2027.